Related Experiment Videos
Carbamazepine in nonresponsive psychosis.
1Department of Psychiatry, University of Washington, Seattle 98195.
The Journal of Clinical Psychiatry
|April 1, 1988
Summary
Carbamazepine may benefit patients with nonresponsive psychosis, particularly those with aggression and agitation refractory to standard neuroleptics. Further research is needed to clarify its role and mechanism in treating psychosis.
Area of Science:
- Psychiatry
- Neuroscience
Background:
- Nonresponsive psychosis presents a challenge, with heterogeneous patient subgroups.
- Some patients remain symptomatic despite adequate neuroleptic treatment.
Purpose of the Study:
- To explore the adjunctive use of carbamazepine in nonaffective, nonepileptic psychotics.
- To identify target symptoms and features indicating carbamazepine's potential efficacy.
Main Methods:
- Review of existing literature, including studies by Neppe and Klein.
- Comparison of blind and nonblind studies on carbamazepine in psychosis.
Main Results:
- Carbamazepine may be beneficial for patients with aggression, interpersonal difficulties, instability, and agitation refractory to neuroleptics.
- The role of temporal-lobe symptomatology is unclear.
- Carbamazepine's mechanism may involve an antikindling-like effect rather than direct antipsychotic action.
Conclusions:
- Carbamazepine shows potential as an adjunctive treatment for specific subgroups of nonresponsive psychosis.
- Further research is essential to elucidate its mechanism and optimal application.
- Psychodynamic factors should also be considered in treatment approaches.